Repligen, a global life sciences company, develops and commercializes innovative bioprocessing technologies that increase efficiencies and flexibility in biotherapeutic manufacturing. As leaders in filtration, chromatography systems, process analytics and fluid management, we are committed to inspiring advances in bioprocessing. We are a trusted partner in the production of monoclonal antibodies, recombinant proteins, vaccines as well as cell and gene therapies. Named one of the fastest growing biotech companies in the USA, the majority of our 18 manufacturing sites are located in the United States (California, Massachusetts, New Jersey, New Hampshire, New York and Texas). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. | Repligen, a global, bioprocessing-focused life sciences company, provides innovative solutions for the advancement of biotherapeutic manufacturing. Experts in filtration, chromatography systems, process analytics, fluid management, and proteins, Repligen is a trusted partner serving the development and manufacture of a wide range of biologics, including cell and gene therapies, mRNA, monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bispecific antibodies, and fusion proteins. Headquartered in Waltham, Massachusetts, USA, Repligen operates across 22 sites, including locations in the United States, Europe, and the Asia-Pacific region. | Inspiring advances in bioprocessing, Repligen is a trusted partner in process intensification, pre-packed chromatography and single-use filtration. Focused on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. As the recognized global leader in Protein A manufacturing, Repligen’s Protein A affinity ligands are routinely used to purify most of the world’s monoclonal antibodies.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
Izon Science
Izon Science is a global leader in nanoparticle characterization, separation, and purification for Exosomes, viruses, and Lipid Nanoparticles (LNPs). Our portfolio includes TRPS and the new NPS (Pulsoid) platforms for precise particle analysis, plus qEV SEC and automated qEV-TFF, Zenco, and DXter systems—supporting workflows from discovery to cGMP-aligned manufacturing. Let’s chat about how we can best support your research. | Izon Science is a global leader in nanoparticle characterization, separation, and purification for Exosomes, viruses, and LNPs. Our portfolio includes TRPS and the new NPS (Pulsoid) platforms for precise particle analysis, plus qEV SEC and automated qEV-TFF, Zenco, and DXter systems—supporting workflows from discovery to cGMP-aligned manufacturing. Let’s chat about how we can best support your research.
iLoF
iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in AI-Driven Drug Discovery, Health Screening & Data Analytics.
Daxiang Biotech
Daxiang Biotech is a leading innovator in organoid-on-a-chip technologies in China and a global provider of integrated microphysiological systems (MPS) solutions for drug discovery, translational research, and precision medicine. Founded in 2018, the company has established a fully integrated, end-to-end platform spanning design, modeling, R&D, manufacturing, and application of human-relevant in vitro systems. Powered by its core technology framework—Organoid-on-a-Chip + AI + Automation—Daxiang develops proprietary instruments, chips, reagents, and advanced human-relevant models to help global life sciences partners improve preclinical decision-making and accelerate development timelines. At the core of its technology is the IBAC® (Integrated Biomimetic Array Chip) platform, which integrates stem cell biology, organoid science, and microfluidics to recreate physiologically relevant human tissue environments in vitro. Based on this platform, Daxiang has developed 50+ organoid culture kits and 100+ humanized physiological and disease models across oncology, liver, gastrointestinal, kidney, brain, and cardiovascular applications. Daxiang’s technologies have been validated by third-party institutions and adopted by leading pharmaceutical companies, biotechnology companies, hospitals, and research institutes. The company has supported multiple IND-enabling programs, helping partners improve translational predictability and reduce reliance on animal models in selected applications. Daxiang Biotech is actively seeking global partnerships with pharmaceutical and biotech companies, CRO/CDMO organizations, research institutions, distributors, and strategic investors. Key collaboration interests include drug discovery services, translational model co-development, precision medicine applications, regional commercialization, and AI-enabled next-generation preclinical platforms.
Cytomos
Cytomos is a cutting edge biotool company revolutionising predictive cell analytics, using the physics of the cell to predict biology. Our proprietary platform, Celledonia® powered by AuraCyt® uniquely predicts cell behaviour by capturing a digital fingerprint of every cell — delivering rapid, high-resolution insights into cell health, phenotype, and function. Celledonia® offers intrinsic, label-free cell analysis at the press of a button, enabling faster, more reliable decisions across research, development, and manufacturing, unveiling a new dimension of cellular understanding. Cytomos provides technology that accelerates discovery, development and scale-up in areas including advanced therapies, cell line development, immunotherapies, differentiation competent cells and biologics. Our mission is to redefine how we understand and control living cells. Celledonia® is a benchtop cell analyser which detects cell features for which there are no biomarkers and provides predictive insights into how those cells will behave during processing. In short, it lets you see what’s coming — before it happens. That predictive power has huge implications for biomanufacturing: faster process optimisation, improved product consistency, and a deeper understanding of what drives cellular performance, quickly. We don’t simply hand over the technology and wish you luck; we work alongside you, integrating the system into your processes to ensure you see the full benefits. We have a dedicated team of scientists and data analysts at our Edinburgh laboratories, who collaborate closely with your teams both in the lab and remotely. Our goal is to make this revolutionary technology both accessible and impactful.
Apxora
APXORA is an agentic AI SaaS platform supporting pharma, biotech, and medtech organizations by connecting financial and commercial decisions with clinical development and R&D through deployable, enterprise‑ready AI workflows. APXORA offers four core solutions: Asset Lifecycle Manager, Portfolio Manager, Clinical Navigator and Research Nexus. They can be deployed independently or as a connected suite, helping teams break down silos, meet security requirements, and adapt seamlessly to existing infrastructure. Together, these solutions create a built-in workflow that not only mirrors but optimizes decision-making. The result is a continuously connected closed loop system spanning early research through portfolio strategy. The platform can be extended with new tools or integrated with legacy systems, forming a living digital twin of the enterprise that strengthens connectivity, accelerates decisions, and improves efficiency at scale. Asset Lifecycle Manager The platform is a dynamic platform built to manage the full lifecycle of strategic assets. From inception to retirement. It enables users to model, monitor, and optimize the performance of each asset across its entire lifecycle. With advanced simulation tools and powered by agentic AI, users can evaluate how market dynamics, pricing strategies, competitive changes, and operational variables impact asset viability over time. Portfolio Manager The platform represents the culmination of a fully integrated decision support ecosystem, connecting every stage of enterprise value creation from early research signals to long term portfolio performance. Built for complex, innovation driven organizations, the Enterprise Suite fosters seamless collaboration across R&D, asset lifecycle management, and strategic planning. Clinical Navigator Clinical Navigator helps clinical teams design, simulate, and optimize trials using patient-level digital twins and predictive models. Built on generative AI and custom LLMs, it enables faster, smarter trial design and identifies regulatory analogs from FDA and EMA landscapes to guide trial planning. Research Nexus Research Nexus enables teams to generate hypotheses, identify novel targets, and explore drug repurposing opportunities. It provides a custom-built knowledge graph as the foundation for agent orchestration and LLM capabilities, unifying scientific and clinical data for rapid exploration and decision-making.